The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

Diabetologia

Volumn 45, Issue 2, 2002, Pages 195-202

  Agerso H ^a   Jensen, L B ^a   Elbrond B ^a   Rolan, P ^b   Zdravkovic, M ^a  

^a NOVO NORDISK A S   (Denmark)

^b Medeval Ltd   (United Kingdom)

Author keywords

Controlled clinical trial; GLP 1; NN2211; Pharmacodynamics; Pharmacokinetics; Safety; Type II diabetes

Indexed keywords

FATTY ACID DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VERTIGO;

ADOLESCENT; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLACEBOS; PROTEIN PRECURSORS; REFERENCE VALUES; SAFETY;

EID: 0036189831     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-001-0719-z     Document Type: Conference Paper

References (38)

1. The glucagon-like peptides
2. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM
3. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
4. Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure
5. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects
6. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients
7. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type II (non-insulin-dependent) diabetic patients
8. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut
9. Glucagon-like peptide-1 7-36: A physiological incretin in man
10. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man
11. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men
12. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men
13. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?)
14. Preserved incretin activity of glucagon-like peptide 1 -7-36 amide- but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus
15. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM
16. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients
17. Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects
18. Glucagonostatic actions and reduction of fasting hyperglycemia bv exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients
19. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus
20. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum
21. Potent derivatives of gglucagon-like peptide-1 with pharmacokinetic properties suitable for once daily aministration
22. Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma
23. Glucagon-Like Peptide-1 infusion must be maintained for 24 hours a day in order to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on treatment with sulphonylurea (SU failures)
24. Albumin binding of insulins acylated with fatty acids: Characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo
25. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs
26. A radioimmunoassay for LY315902, an analog of glucagon-like insulinotropic peptide, and its application in the study of canine pharmacokinetics
27. Pharmacokinetic profile of the long-acting GLP-1 derivative NN2211 in healthy male subjects
28. Glucose lowering of the protracted GLP-1 derivative, NN2211, in the β-cell reduced minipig
29. The long acting GLP-1 derivative NN2211 markedly slows the development of diabetes in the male zucker diabetic fatty rat
30. NN2211, a long acting derivative of GLP-1, lowers blood glucose in ob/ob and db/db mice
31. An Immunoassay for the GLP-1 derivative NN2211
32. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
33. Glucagon-like peptide-1: A potent regulator of food intake in humans
34. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans
35. Is glucagon-like peptide 1 an incretin hormone?
36. LY307161: A protease-protected analogue of GLP-1, with enhanced activity and time action in vivo
37. The GLP-1 analogue, LY307161, potently lowers post prandial blood glucose in subjects with Type II diabetes
38. Effects of five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes